Loading...
•
Dec 31, 2021
Gilead Sciences Q4 2021 Earnings Report
Announced results for the fourth quarter of 2021, with Biktarvy sales increasing year-over-year by 22% amid a decrease in total revenue due to reduced Veklury demand.
Key Takeaways
Gilead Sciences reported a 2% decrease in total Q4 2021 revenue to $7.2 billion, impacted by lower Veklury sales, but HIV product sales increased by 7%. Diluted EPS decreased to $0.30, and non-GAAP diluted EPS decreased to $0.69, primarily due to charges related to a legal settlement and the Arcus collaboration opt-in.
Total Q4 2021 revenue decreased by 2% year-over-year to $7.2 billion.
Biktarvy sales increased 22% year-over-year in Q4 2021.
Diluted EPS decreased to $0.30 for Q4 2021, while non-GAAP diluted EPS decreased to $0.69.
Gilead generated $3.2 billion in operating cash flow during Q4 2021.
Gilead Sciences
Gilead Sciences
Gilead Sciences Revenue by Segment
Gilead Sciences Revenue by Geographic Location
Revenue by Segment
HIV Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Gilead provided full-year 2022 guidance, including total product sales between $23.8 billion and $24.3 billion, Veklury sales of approximately $2.0 billion, and non-GAAP earnings per share between $6.20 and $6.70.
Positive Outlook
- Total product sales between $23.8 billion and $24.3 billion.
- Total product sales, excluding Veklury, between $21.8 billion and $22.3 billion.
- Veklury sales of approximately $2.0 billion.
- Earnings per share between $4.70 and $5.20.
- Non-GAAP earnings per share between $6.20 and $6.70.
Challenges Ahead
- Uncertainty around the duration and magnitude of the COVID-19 pandemic.
- Potential adverse revenue impacts from COVID-19.
- Increases in R&D expenses.
- Uncertainty in potential revenues from Veklury.
- Financial guidance is subject to a number of risks and uncertainties.